Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | KIT | P10721 | 6/20 | 0.34 |
| ▸ | WNT3A | P56704 | 4/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.33 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.33 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8940725 | 0.90 | JAK2 (0.34) | JAK3CYP3A4ROCK1JAK2 | |
| SCHEMBL8986181 | 0.85 | JAK3 (0.36) | JAK3KITWNT3ABRD4SMARCA2 | |
| SCHEMBL8940862 | 0.76 | JAK2 (0.34) | JAK3CYP3A4ROCK1JAK2 | |
| SCHEMBL8940767 | 0.74 | JAK2 (0.34) | JAK3JAK2 | |
| SCHEMBL8940454 | 0.72 | JAK2 (0.38) | JAK3CYP3A4ROCK1JAK2 | |
| SCHEMBL8940702 | 0.72 | MAP3K11 (0.39) | JAK3JAK2 | |
| SCHEMBL8940882 | 0.72 | JAK3 (0.36) | JAK3KITCYP3A4ROCK1JAK2 | |
| SCHEMBL8941163 | 0.72 | NTRK1 (0.38) | JAK3KITCYP3A4ROCK1JAK2 | |
| SCHEMBL8940227 | 0.70 | JAK2 (0.42) | JAK3CYP3A4ROCK1JAK2 | |
| SCHEMBL13887797 | 0.69 | CYP3A4 (0.43) | JAK3CYP3A4ROCK1JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188281-B2 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-29 | — | — | US | disclosed |
| US-20090176763-A1 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176763-A1 | Azaindoles useful as inhibitors of JAK and other protein kinases | JAK3, JAK2, JAK1 | JAK3 1/4885KIT 804/4885WNT3A 2076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.